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Significance statement 
National and international guidelines recommend supportive approaches to acute kidney 
injury (AKI) management. Organisational strategies to improve delivery of AKI care have not 
previously been tested in multi-centre randomised studies. This paper describes a 
pragmatic, multi-centre, cluster-randomised study of AKI e-alerts, an AKI care-bundle and a 
programme of education across five UK hospitals. The intervention did not alter the primary 
outcome of 30-day mortality but did result in improvements in hospital length of stay, a 
reduction in AKI duration and an increase in AKI incidence reflecting improved recognition. 
These results in combination with previous evidence show that strategies to improve the 
systematic delivery of supportive AKI care can lead to improvements in patient outcomes. 
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Abstract 
Background: Variable standards of care may contribute to poor outcomes associated with 
acute kidney injury (AKI). We evaluated whether a multifaceted intervention (AKI e-alerts, an 
AKI care bundle and an education programme) would improve delivery of care and patient 
outcomes.  
 
Methods: A multi-centre, pragmatic, stepped-wedge cluster randomised trial (SWCRT) was 
performed in five UK hospitals. The intervention was introduced sequentially across fixed 
three-month periods until all hospitals were exposed. The intervention schedule was 
randomly determined. All patients with AKI aged ≥18 years were included. The primary 
outcome was 30-day mortality, with pre-specified secondary endpoints and a nested 
evaluation of care process delivery. The nature of the intervention precluded blinding, but 
data collection and analysis were independent of project delivery teams.  
 
Findings: 24,059 AKI episodes were studied. Overall 30-day mortality was 24.5%, with no 
difference between control and intervention periods (OR 1.04, 95% CI 0.91-1.21). Hospital 
length of stay (LoS) was reduced with the intervention (-0.2days (95% CI -0.5 to 0.1), -
0.7days (-1.3 to -0.2) and -1.3days (-2.5 to -0.2) at the 0.3, 0.5 and 0.7 quantiles 
respectively). AKI incidence increased (adjusted incidence rate ratio 1.12, 95% CI 1.03-1.22) 
with a parallel increase in the proportion of patients with a coded diagnosis of AKI. Process 
measures were assessed in 1048 patients, with improvements seen in several metrics 
including AKI recognition, medication optimisation and fluid assessment.  
 
Conclusions: A complex, hospital-wide intervention to reduce harm associated with AKI did 
not alter 30-day AKI mortality but did result in reductions in LoS, accompanied by 
improvements in in quality of care. AKI incidence increased, likely reflecting improved 
recognition.  
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Introduction 
Acute kidney injury (AKI) is common and is associated with markedly elevated short-term 
morbidity and mortality, subsequent risk of chronic kidney disease (CKD) and large 
increases in healthcare resource utilisation.1 AKI occurs in 5%–22% of hospital admissions 
and mortality rates exceed 20%, rising to greater than 50% in those most severely affected.2 
In the absence of specific therapies, AKI management requires methodical delivery of basic 
elements of care.3 Despite universal recommendation of this approach in national and 
international guidelines,4-6 successive reports have described variation in the quality of 
clinical care for AKI, with poor standards of care associated with worse outcomes.7-10 Whilst 
there are no proven interventions for AKI, the evidence-base to support organisational level 
interventions to address variations in AKI care is also lacking. In the only previous 
randomised trial, a text message alert for AKI did not change physician behaviour or patient 
outcomes, possibly because the alert was introduced without recommendations for care or 
other interventions.11 Conversely, several non-randomised studies testing broader 
interventions, generally using before-after comparisons, have shown more positive results 
including reductions in mortality, although methodological concerns prevent firm conclusions 
from being made.12-15 Additionally, all but one of these studies are single-centre, so do not 
inform whether successful interventions retain effectiveness if scaled to other organisations. 
We therefore sought to address some of these knowledge gaps by performing a multicentre, 
randomised trial to test the hypothesis that a complex intervention for AKI (comprising AKI e-
alerts, an AKI care bundle and a programme of AKI education) would improve standards of 
care delivery and lead to better patient outcomes.  
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Methods 
Study design and participants 
Over a 27-month period we conducted a multi-centre, pragmatic stepped-wedge cluster 
randomised trial (SWCRT). The study was conducted using a published protocol,16 which 
was consistent with the extension to cluster randomised trials of the CONSORT 2010 
document17 and recommendations for SWCRTs.18 The protocol and statistical analysis plan 
were published on the NHS England Think Kidneys Programme website19 and are included 
in Supplementary Material.   
The SWCRT design allowed differentiation between the effect of the intervention and 
independent time-related factors whilst avoiding ethical concerns around withholding 
treatment in line with minimum care standards, with all sites exposed to the intervention by 
study end. Cluster randomisation avoided contamination of the control group that would 
likely occur with randomisation at a patient level.  
The intervention, designed to reduce avoidable harm associated with AKI, was introduced 
across five National Health Service (NHS) hospital sites representing academic and non-
academic centres as well as those with and without onsite nephology services. Data 
collection and analysis were conducted independently by researchers not involved in the 
delivery of the intervention at the participating hospitals.  
The SWCRT design involved delivery of the intervention sequentially to one hospital at a 
time across fixed three-month periods until all five hospitals were exposed to the intervention 
(Figure 1). A six-month baseline period prior to any of the sites introducing the intervention 
was followed by five three-month implementation steps (one hospital per step). The three-
month time-period during which a site introduced the intervention, when it was expected not 
to have reached full effect, was considered a transition period and excluded from analyses. 
All sites had a minimum of one three-month period of exposure to the intervention following 
the transition period.  
We included all patients aged ≥18yrs who were hospitalised for at least one night during the 
study period and sustained AKI during that admission. Patients were defined as having AKI 
if they had an inpatient serum creatinine result consistent with a modified Kidney Disease: 
Improving Global Outcomes (KDIGO) definition of AKI, as identified by the NHS England 
algorithm. A full description of the algorithm has been published previously,20 but in brief the 
algorithm applies the KDIGO criteria to an individual’s current serum creatinine value using a 
baseline value defined as either the lowest in the last seven days, or a median of values 
from the preceding 8-365 days depending on availability of previous results.  Urine output 
was not used to define AKI for pragmatic reasons. The only exclusion criterion was chronic 
dialysis for end-stage kidney disease. Derbyshire Research Ethics committee designated 
the study as service improvement and waived the requirement for individual patient consent. 
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Transfer and collation of patient data by the UK Renal Registry (UKRR) was approved by 
the Health Research Authority under section 251 of the NHS Act 2006.  
 
Randomisation and blinding 
The unit of randomisation (the cluster) was the participating hospital. Randomisation was 
performed by the UK Renal Registry (UKRR) and took place on the 11th of May 2015 using 
random number generation (SAS-9.3, RANUNI function). The first hospital commenced 
implementation in June 2015. There were no delays to the SWCRT sequence. Due to the 
nature of the intervention, blinding was not possible.  
 
Intervention 
The intervention had three components designed to improve AKI recognition and the 
delivery of basic elements of AKI care, as recommended by National Institute for Health and 
Care Excellence clinical guideline CG169, and other national and international guidelines.4-6, 
21 The components of the intervention were: 
• An AKI electronic detection and alerting system, 
• An AKI care bundle, containing individual elements pertaining to assessment, 
investigation and basic management of AKI (summarised in Table 1A),22 
• An educational program to raise awareness and knowledge of AKI in healthcare 
workers (summarised in table 1B). 
Introduction of the intervention was supported by a structured approach to change 
management, described elsewhere.16 This included permissive tailoring of the elements of 
the intervention to fit each hospital’s local context, but the same basic elements were 
present across all sites. The electronic AKI detection system was uniform across all sites, 
conforming with a nationally mandated specification.20 Audit during the set up phase 
ensured that the algorithm was running correctly in each laboratory. The detection algorithm 
ran at all sites throughout the study period, with alerts being released to clinicians at the 
point when the hospital was randomised to introduce the intervention. The alert message 
notified the healthcare professionals that the patient had sustained AKI, the stage of AKI and 
included an advice message advising a clinical response/review of the patient and sign-
posting of local AKI resources (guidelines, care bundles). All sites also adopted an active 
element to the alert, in that the duty biochemist would telephone AKI stage 2 and 3 results to 
the clinical areas from which the blood tests were sent (as opposed to a purely ‘passive’ 
alert within the results reporting system that relies on clinicians seeing the result 
autonomously).  
The care bundles at each site all contained the same core elements (Table 1A) although 
initial care bundle content and design was refined in response to end-user feedback during 
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the first three months of use. This led to a degree of variation in the number of actionable 
items in the care bundles between hospitals. Care bundles were delivered in paper form that 
were integrated into patients’ hospital notes apart from one centre where the care bundle 
was in electronic form.  
Education was mainly delivered by face to face teaching across a number of different 
settings, but also included the development of educational materials, e-learning and 
awareness raising. Formal teaching sessions were typically delivered using PowerPoint 
presentations, whilst ad hoc or opportunistic teaching on wards were focussed around real 
time patient examples or signposting project resources. A summary of educational activities 
that were delivered in each hospital is shown in table 1B.  
The intervention was delivered by an AKI project team at each hospital, which consisted of 
staff provided by the central team (project managers CJ, NJ, MJ), principle investigators 
(YS, NS, AJL, JS, RR) and hospital staff not funded by the project.  
 
Outcomes 
The primary outcome was 30-day mortality after an episode of AKI, comparing control and 
intervention periods. Pre-defined secondary outcomes included: incidence of hospital 
acquired AKI; AKI progression to higher stages; incidence of individual AKI stages; and 
length of hospital stay (LoS).16 We defined hospital acquired AKI as that with its onset 
>24hrs after hospital admission, and AKI progression as an increase of  1 AKI stage from 
time of detection.23 Following LoS analysis, a post hoc analysis was undertaken for duration 
of AKI (calculated as days between first and last serum creatinine results that met the 
definition of AKI). Technical issues prevented data collection for two pre-specified secondary 
endpoints (number of critical care bed days and renal recovery).  
 
Outcome data were collected using biochemical results to identify episodes of AKI, which 
were then linked to data from each hospital’s patient administration system (PAS) to 
determine patient identifiers and demographics, date of admission and discharge, all 
diagnosis codes from the index admission (as per International Classification of Diseases, 
10th Revision (ICD-10) and Charlson co-morbidity score)24 and date of death. These data 
were transferred directly to the UKRR from each site independently of the study teams and 
were analysed by an independent statistician. NHS-tracing was performed by the UKRR at 
the end of the study to identify any additional out-of-hospital deaths. Summary data for each 
hospital were generated for each three-month period for total number of adult admissions 
grouped by age, gender and ethnicity to allow calculation of AKI incidence. In September 
2016, there was an IT failure of the laboratory information management system (LIMS) that 
served three of the participating hospitals. This meant that the AKI detection algorithm was 
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not available and laboratory data collection was not possible during this period. For this 
reason, the trial was extended to allow an extra period of data collection (Dec 2016–Feb 
2017) so that the planned number of data collection blocks was achieved; data from the 
affected period were excluded. 
 
Process outcomes included the proportion of patients receiving elements of basic care (AKI 
recognition, fluid assessment, medication review, investigation, senior clinician/specialty 
review, care bundle usage), as determined by repeated cycles of clinical audit (30 sequential 
patients per site from each three-month data collection period, giving a planned sample of 
1050 case notes evenly distributed across AKI stages 1, 2 and 3). A standard data collection 
form and data specification sheet were used; these are included as Supplementary Material.  
 
Sample size calculation 
An a-priori sample size calculation was undertaken.25 The total number of annual hospital 
admissions across the five sites (434,000) was taken from the Health and Social Care 
Information Centre (www.hscic.gov.uk, April 2014-March 2015). The most conservative 
published rates for assumptions of the proportion of hospital admissions with AKI (2.5%)26 
and 30-day mortality (16%)27 were used. Power was set at 80%, alpha at 0.05 and a range 
of values for intra-cluster correlation between 0.01-0.2 were considered. With a trial study-
time of two years, five participating sites (one per randomisation step), one transition period 
per site and the design effect of the SWCRT,25 we calculated that to detect an absolute 
decrease in 30-day-mortality of 3.2%,12, 13 10,850 AKI episodes should be studied. 
 
Statistical analysis 
Analysis of 30-day mortality was undertaken using multilevel logistic regression at the 
individual patient level with hospital modelled as a random effect, and adjusting for time, 
patients’ co-variables (age, gender, comorbid conditions), and the effect of seasonality. We 
pooled time into quarterly intervals, treated as equally spaced in analytic models. Only first 
hospitalisations in those patients with multiple AKI episodes were included; results were 
similar when analyses used last or multiple episodes per patient. The primary outcome 
response was the estimated mortality odds ratio for the intervention versus control period.  
Secondary analyses were also undertaken at the individual patient level, again adjusting for 
time, patients’ co-variables (age, gender, comorbid conditions), cluster (hospital) and the 
effect of seasonality. AKI incidence was calculated using the total number of overnight 
hospitalisation episodes within each time period as the denominator, and analysed using 
multilevel negative-binomial regression. AKI progression was analysed as a binary outcome 
for each overnight hospitalisation episode using multilevel logistic regression as for the 
  10 
primary outcome (excluding AKI stage 3). The hospital length of stay (LoS) and AKI duration 
data were highly skewed, and the fit of prespecified Poisson and negative binomial 
regression models were poor (inadequate correlation between observed versus predicted 
values). Therefore, quantile regression models were fitted to allow comparisons at points 
across the whole distribution (after adjustment for age, gender, comorbid conditions, time, 
season, centre) in addition to comparison of average values; this approach does not make 
assumptions about the distribution of the dataset and is robust against the presence of gross 
outliers.28, 29 For LoS analyses, only patients who survived to hospital discharge were 
included. Statistical analyses were conducted at the UKRR in collaboration with the 
University of Bristol, using Stata MP12 and SAS 9.3. 
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Results 
During the study period, there were a total of 316,413 hospital admissions from which a total 
of 24,059 AKI episodes occurred in 20,179 patients, giving a crude incidence of 7.6 AKI 
episodes/100 admissions. During the control period there were 14,042 episodes (58.4%), 
with 10,017 (41.6%) in the intervention period. The distribution across AKI stages was as 
follows: 62% of episodes were AKI stage 1, 21% were stage 2 and 17% were stage 3, and 
12,507 episodes (52%) were hospital-acquired. Patient demographics in control and 
intervention periods are shown in Table 2, and data for individual hospitals in Supplementary 
Material. Differences in the populations served by each site and the SWCRT design 
(meaning that sites contributed different amounts of data to control and exposed periods 
depending on their place in the randomisation sequence) resulted in differences in patient 
demographics between control and intervention periods. These differences between control 
and intervention periods were not seen when comparing patient demographics at a hospital 
level. We also observed a significant effect of season on AKI incidence, with higher AKI 
rates observed during winter (rate ratio in winter (December-February) of 1.08, 95% CI 1.02-
1.13, p=0.006 as compared with spring (March-May)). Outcome analyses were adjusted for 
these co-variables.  
 
30-day mortality 
Crude 30-day mortality across the entire study period was 24.5%. 30-day mortality was not 
affected by the intervention; in the fully adjusted model (Table 3), the odds ratio for 30-day 
mortality in the intervention period versus the control period was 1.04 (95% CI 0.91-1.21, 
p=0.55). Analyses performed for individual AKI stages and for community- and hospital-
acquired AKI separately also did not show any difference in 30-day mortality between 
intervention and control periods.  
 
AKI incidence 
After adjustment for other variables, the incidence of AKI was higher in the intervention 
period as compared to the control period (incidence rate ratio (IRR) 1.12, 95% CI 1.03-1.22, 
p=0.009). The same effect size was observed across each stage of AKI when analysed 
separately (Supplementary Material). The increase in AKI incidence was mirrored by a large 
increase in the proportion of patients with a coded diagnosis of AKI (ICD-10 code N17.x) 
during the intervention period (adjusted IRR 1.27, 95% CI 1.15-1.39, p<0.001), suggesting 
improved AKI recognition.  
 
Hospital length of stay (LoS) and AKI duration 
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A total of 18,887 admissions in which the patient was discharged alive were included in the 
LoS quantile regression analyses. The median hospital LoS for all AKI admissions was 9 
days (IQR 4-19). LoS was reduced in the intervention period, as shown in Figure 2. The 
effect was seen in those with longer LoS (from quantiles 0.5 upwards). At the 0.5 quantile, 
the effect size was a reduced length of stay of -0.7 days (95% CI -1.3 to -0.2, p=0.04), 
extending to -1.3 days (95% CI -2.5 to -0.2, p=0.03) at the 0.7 quantile. When the analysis 
was repeated including all admissions regardless of whether or not the patient was alive at 
discharge, the same pattern of results was observed (Supplementary Material).  
Similarly, we observed a reduction in AKI duration during the intervention period; these data 
are shown in Figure 3. The median duration of AKI was 2 days (IQR 1-4). The effect of the 
intervention was seen in those at the 0.7, 0.8, and 0.9 quantiles; at the 0.8 quantile the 
reduction in duration of AKI was -0.7 days (95% CI -1.2 to -0.2, p=0.01).  
Quantile regression was chosen in place of the pre-specified analyses for LoS and AKI 
duration as both Negative Binomial and Poisson regression showed a significant lack of 
model fit with poor residual plots. However, results from these analyses were consistent with 
those from quantile regression: with Negative Binomial regression, LoS was decreased in 
the intervention period by 6.6%, 95% CI 1.3-11.6%, p=0.015; with Poisson regression LoS 
was decreased by 6.2%, 95% CI 4.7-7.7%, p<0.001; with Negative Binomial regression, AKI 
duration decreased by 14.7%, 95% CI 8.8-20.3%, p<0.001; and with Poisson regression AKI 
duration decreased by 14.0%, 95% CI 11.4-16.5%, p<0.001. 
 
AKI progression 
AKI progression was assessed only in patients with AKI stage 1 or 2 at time of AKI onset 
(21,672 AKI episodes). There was no significant effect of the intervention on AKI progression 
in the fully adjusted model (OR 0.94, 95% CI 0.8-1.1, p=0.4). These data are shown in Table 
4. A total of 630 patients (2.6%) were coded as receiving acute renal replacement therapy 
(RRT); the odds ratio of receiving RRT during the intervention period as compared to the 
control period was 1.1 (95% CI 0.8-1.6).  
 
Sensitivity analyses 
Because of the effect of season on AKI incidence and outcome, we performed a sensitivity 
analysis to test the effect of the intervention on mortality during winter as compared to other 
seasons by adding an interaction term to the model. We also explored whether time from a 
site’s initial exposure to the intervention was important. This tested whether an effect was 
sustained or diminished over time, or if there were differences in the time required to reach 
maximal effect. Neither interaction showed differences in effect by season or time from 
exposure. 
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A sensitivity analysis for AKI progression was also performed that included patients with AKI 
stage 3 who progressed to RRT as well as those with AKI stages 1 and 2. This produced 
similar results to the primary analysis, with no significant difference between control and 
intervention periods.  
 
Process outcomes 
Process measures were assessed in 1,048 patients. Comparisons between control and 
intervention periods are shown in Figure 4. Care bundle usage increased from 0% to 40.2% 
from control to intervention periods. Increases were also seen in AKI recognition (69.4% 
versus 88.8%), medication review (60.1% versus 71.3%), fluid assessment (74.4% versus 
91.2%) and urinalysis (37.4% versus 64.7%). Changes in rates of specialist referral, renal 
imaging and urinary catheterisation were not seen. There were differences between sites in 
the degree of improvement and baseline levels of compliance; these data are included in 
Supplementary Material.  
 
  14 
Discussion 
In this multi-centre, stepped-wedge cluster randomised trial, a complex organisational-level 
intervention did not alter 30-day AKI mortality, but did result in shorter duration of AKI 
episodes, a reduction in hospital length of stay and improved AKI recognition. These findings 
were consistent across sensitivity and sub-group analyses.  
 
Multiple reports from a variety of care settings consistently show that AKI in hospitalised 
patients is both common and associated with poor outcomes.30, 31 In the absence of specific 
therapies, efforts to improve outcomes for patients have focussed on increasing the 
consistency and quality of supportive care for AKI, exemplified by national and international 
campaigns such as the International Society of Nephrology ‘0by25’ campaign and the ‘Think 
Kidneys’ national programme in England.21, 32 In parallel with these initiatives, there is a need 
to test the effectiveness of potential strategies and how they should be delivered across 
different health care systems. Our aim was to establish a more rigorous approach to this 
than previously, and evaluate an intervention aimed at improving AKI care within a 
multicentre randomised study design. The pragmatic trial methodology allowed adequate 
statistical power, with numbers of cases and event rates exceeding assumptions in the 
sample size calculation. Adherence to the allocated times for implementation was excellent 
across all five sites, and use of the UKRR infrastructure allowed the study to be undertaken 
efficiently and with independent data collection and analysis. The demographics of the study 
population were consistent with previous epidemiological studies,27, 33 and the higher AKI 
incidence and mortality in winter, recently described elsewhere,34 was an important 
observation that required adjustment in statistical modelling and has relevance to the design 
of future studies. The SWCRT is a relatively novel trial design that is increasingly popular, 
particularly in the evaluation of complex interventions. It is more robust than before-after 
studies as it allows for differentiation between the effect of the intervention and independent 
time-related factors (i.e. changes that would have happened anyway). In our study, due to 
the nature of the intervention, it overcame the problem of contamination of the control group 
(healthcare professionals within individual hospitals exposed to the intervention but treating 
patients in both control and intervention groups) that would have occurred with 
randomisation at the patient level. There are other advantages; SWCRTs are well suited to 
pragmatic aspects of the roll-out of complex interventions; ethical issues are avoided if 
concerns about withholding an intervention in the control arm exist; and efficient trial design 
is possible. Disadvantages include the need for more complex statistical approaches 
(including those to avoid confounding), biases that may arise if cluster size is too small; and 
if individual patient data collection is required that can lead to selection bias.18 
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We did not observe any change in 30-day mortality, and this held true across a number of 
subgroup analyses. A previous single-centre randomised trial demonstrated that an isolated 
e-alert for AKI did not result in any change in physician behaviour or patient outcomes.11 Our 
results differ in that we did observe improvements in AKI care delivery, including an increase 
in care bundle usage from zero during the control period to approximately 40% with the 
intervention. One interpretation of our results is that better AKI care does not translate into 
improved mortality, although an alternative explanation is that uptake of the intervention was 
incomplete across participating sites, whereas outcomes were measured on a hospital-wide 
basis. This would be supported by the bundle completion rates. Hence, even if an 
intervention is effective at changing provider behaviours, a challenge remains concerning 
spread and sustainability across an organisation. Previous studies that have reported 
reductions in patient mortality following complex interventions for AKI have generally used 
less robust methodology (e.g. before-after comparisons that cannot exclude effects of 
temporal trends on outcomes, or limited statistical analysis); results from single-centre 
studies may also be subject to attenuation of effect size when scaling this type of 
intervention to a larger number of sites.   Our study was adequately powered to detect 
similar size reductions in mortality, although a recent study with a before-after design is 
notable for the very large sample size (>64,000 patients) required to demonstrate a small but 
significant reduction in mortality with the introduction of computer decision support for AKI.15 
However, our study was more than double the estimated sample size and we did not 
observe any trend towards mortality reduction. The primary endpoint of 30-day mortality was 
chosen based on previous single centre quality improvement studies that did show 
improvements in this outcome.12, 13 However, mortality associated with AKI is driven by 
multiple factors, including effects of co-morbidity and co-existing acute illness in addition to 
effects from AKI.35 In view of our findings, it may be advisable for future trials of complex 
interventions for AKI to consider alternative primary outcomes, particularly those which are 
organ-specific (e.g. AKI duration, recovery of renal function) but which retain importance 
from a patient’s perspective.  
 
There was a beneficial effect of the intervention on hospital length of stay and AKI duration. 
The effect of the intervention on LoS was only apparent in those with a longer hospital stay. 
A similar pattern was seen with AKI duration, likely explained by limited potential for 
improvement in those with very short LoS or AKI duration. The positive effects of the 
intervention on LoS may be considered relatively modest for the individual patient, but given 
the very large numbers of patients who sustain AKI this could translate into a significant 
health economic benefit; in England alone it is estimated that there are >800,000 hospital 
admissions with AKI annually.36 Our post hoc analysis to examine the effect on AKI duration 
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was undertaken to explore plausible reasons by which the intervention could directly reduce 
LoS. Its inclusion was further justified as we were unable to study the effect of the 
intervention on another prespecified secondary end point (critical care bed days). It is 
possible that the reduction in AKI duration may have a positive benefit on long term patient 
outcomes as AKI duration has been shown to be a very strong independent predictor of both 
subsequent CKD and long term mortality.37, 38 Unfortunately, reliable data collection to 
evaluate renal recovery in this study was not possible.  
 
We also observed an increase in the incidence of AKI during the intervention period. This 
was not an effect of time or season. The most likely explanation is improved testing and 
recognition, resulting from healthcare staff education. This is supported by the parallel 
increase in AKI diagnostic coding and the improvement in AKI recognition seen in the nested 
study of process measures. A similar effect has been reported in other studies.15 
Importantly, in terms of interpreting the effect of the intervention on other outcomes, the 
increase in AKI incidence was seen equally across all stages of AKI, suggesting that 
improvements in LoS and AKI duration were not an artefact of a disproportionate increase in 
AKI stage 1 during the intervention.  
 
There are some limitations of this study. The use of an electronic algorithm to identify AKI 
cases may result in some misclassification of a small number of patients with AKI (e.g. 
progressive CKD).39 The inclusion of data from such patients may produce a small bias in 
favour of the null hypothesis. Using serum creatinine criteria without urine output may result 
in an under-estimation of AKI incidence, but was the only pragmatic approach for hospital-
wide assessment of AKI where the majority of patients do not have hourly urine output 
measurements. Results from analyses of secondary and exploratory outcomes were not 
adjusted for the effects of multiple testing and need to be interpreted in light of this. The 
potential for the change in AKI incidence to affect other outcomes should be noted, although 
we found no evidence to suggest that there was a shift towards less severe AKI in the 
intervention period, nor did we see any change in mortality which would be expected if 
severity of AKI was altered. The audit of process measures was conducted in a subgroup of 
patients and therefore no direct inferences can be drawn regarding these results and 
outcomes. The LIMS failure interrupted data collection for a short period, although this was 
successfully mitigated by extending the study duration. Finally, our findings may not be 
generalisable to other healthcare systems that differ substantially from the National Health 
Service in England.  
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In conclusion, a strategy to reduce avoidable harm associated with AKI did not alter 30-day 
AKI mortality but was effective in reducing duration of AKI episodes and hospital length of 
stay, and resulted in better AKI recognition. These results support a continued focus on 
improving the delivery of person-centred AKI care across acute specialities.  
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Tables and Figures  
 
Figure 1 
Schematic of the stepped-wedge study design. After a six-month period of baseline data 
collection, the intervention (hospital wide AKI e-alert, care bundle and education 
programme) was sequentially introduced to participating sites across fixed three-month 
periods of time until all sites were exposed to the intervention. Data collection occurred at 
each step of the wedge, including in the post intervention period. The three-month time-
period during which a site introduced the intervention, when it was expected not to have 
reached full effect on outcomes, was considered a transition period and excluded from 
analyses. All sites had a minimum of one three-month period of exposure to the intervention 
following the transition period. The sequence was determined by random number generation 
and the order of the hospitals was as follows: 1. Frimley; 2. Bradford; 3. Ashford and St 
Peters; 4. Leeds General Infirmary; 5. Leeds St. James’.  
 
Figure 2 
Change in hospital LoS (in days) comparing the effect of the intervention against control 
period. LoS is shown on the y-axis at different quantiles of the distribution. The solid line 
represents the estimated changes in LoS distribution quantiles from before to after the 
introduction of the intervention across the different quantiles of the distribution after 
adjustment for time, age, gender, comorbid conditions, cluster (hospital) and seasonality, 
and the shaded area represents 95% CI. Results show a reduced LoS during in intervention 
period (from quantiles 0.5 upwards, effect size and median LoS at individual quantiles 
shown in the table).  
 
Figure 3 
Change in AKI duration (in days) comparing the effect of the intervention against control 
period. AKI duration is shown on the y-axis at different quantiles of the distribution. The solid 
line represents the estimated changes in AKI duration distribution quantiles from before to 
after the introduction of the intervention across the different quantiles of the distribution after 
adjustment for time, age, gender, comorbid conditions, cluster (hospital) and seasonality, 
and the shaded area represents 95% CI. Results show a reduced AKI duration during in 
intervention period (from quantiles 0.8 onwards, effect size and median AKI duration at 
individual quantiles shown in the table).  
 
Figure 4 
  22 
Change in measures of AKI care comparing control and intervention periods. Urinary 
catheterisation was included as a balancing measure, and we did not observe an unintended 
increase in the proportion of patients catheterised for reasons other than relief of urinary 
obstruction.  
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Core elements of AKI care bundle common across all sites 
Assess volume status and optimise blood pressure 
 
Treat sepsis  
 
Review medications and stop those contributing to AKI  
 
Perform urinalysis  
 
Referral (to nephrology or critical care outreach) for AKI stage 3, AKI with complications 
 
Table  1A.  
Core elements that were included in care bundles at each of the Tacking AKI study sites. Sites were 
permitted to tailor the appearance of care bundles, and some sites included additional elements e.g. 
additional investigations into cause of AKI, manage hyperkalaemia, informing patient of presence of 
AKI.  
 
Type of education 
session 
Number 
of 
sessions 
per 
centre 
Target audience Audience 
size 
Duration 
Launch event 1 All members of staff welcome. 
Hospital chief executive, medical 
director, chief nurse attended 
30-50 1 hour 
Hospital grand 
rounds * 
2 All grades of physicians, doctors in 
training and open to other specialties 
who wish to attend 
40-80 1 hour 
Departmental 
educational or 
clinical governance 
meetings 
3-8 Departmental teaching to a range of 
specialties (e.g. emergency 
medicine, acute medicine, surgery, 
urology, rheumatology, elderly care)  
10-20 1 hour 
Postgraduate 
teaching for doctors 
in training * 
3 per year 
(one for 
each 
grade of 
doctor) 
AKI teaching as part of curriculum 
(essential teaching) for doctors in 
training, attendance often mandatory 
20-40 1-2 hours 
Induction teaching 
for new staff * 
1-3 Shorter sessions, more focused on 
process rather than education per se 
20-40 15mins 
Nursing, pharmacy 
and advanced 
practitioner teaching 
2-3 Varied between centres, from small 
group teaching to formal AKI study 
days for large groups  
5-70 1 hour-
whole day 
Ward based teaching 
sessions 
5-10 Formal teaching sessions at ward 
level 
1-10 5-30 min 
Ad hoc teaching 
sessions 
20+ Informal teaching delivered by 
various members of the AKI team, 
included reminders of resources, 
case-based teaching 
1-3 Varied, 
usually 
only 
minutes 
Other activities: 
• Publicity activities 
• E-learning, use of online teaching videos 
Table 1B 
Description of educational programme activities that were delivered across sites.  
* signifies activities that were already in place prior to the study.  
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 Control Intervention 
Number of AKI episodes  14,042 10,017 
   
% male 50.3% 48.1% 
   
Age-group (%)   
18-59 23.1% 20.3% 
60-69 15.7% 15.3% 
70-79 23.7% 23.5% 
80-89 27.2% 29.8% 
90+ 10.3% 11.1% 
   
Median age (years) 75.4 76.6 
   
Charlson co-morbidity score   
0 16.4% 18.8% 
1 20.3% 21.0% 
2 20.2% 19.4% 
3+ 
 
Individual co-morbidities  
Previous myocardial infarction 
Heart failure 
Previous stroke 
Diabetes mellitus 
Chronic kidney disease 
Chronic liver disease  
43.1% 
 
 
15.1% 
23.0% 
7.0% 
27.3% 
22.0% 
8.8% 
40.8% 
 
 
14.4% 
22.6% 
6.9% 
28.1% 
23.5% 
7.0% 
   
Ethnicity   
Afro-Caribbean 1.4% 0.8% 
South-Asian 5.5% 5.9% 
Other 2.8% 2.8% 
White 86.1% 85.3% 
Missing 4.2% 5.2% 
   
Social deprivation score* (%)   
1 (least deprived) 23.6% 36.4% 
2 17.8% 16.7% 
3 16.0% 15.8% 
4 15.7% 13.3% 
5 (most deprived) 26.8% 17.6% 
Missing 0.1% 0.2% 
   
Peak AKI stage (% per stage)   
1 60.6% 64.5% 
2 21.4% 19.8% 
3 18.0% 15.7% 
   
Hospital-acquired AKI** (%) 53.8% 49.4% 
   
 
Table 2 
Patient demographics in control and intervention periods. Please note that unadjusted data are 
shown, and differences between control and intervention populations largely reflect the different 
amounts of data submitted to control and intervention periods as a result of the stepped wedge cluster 
randomised trial design. There were no major differences between control and intervention periods 
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(including in AKI severity) when patient demographics were analysed at a hospital level; these data 
are available in Supplementary Material.  
Abbreviations: Ashford: Ashford and St Peter’s Hospital; Bradford: Bradford Royal Infirmary; Frimley: 
Frimley Park Hospital; LGI: Leeds General Infirmary; LSJ: Leeds St James’ Hospital. 
* Social deprivation scores show the proportion of patients in each quintile of the Index of Multiple 
Deprivation.  
** Hospital acquired AKI defined as AKI onset >24 hours after hospital admission.  
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Multilevel logistic regression for mortality 
 Odds ratio 95% CI p-value 
Intervention (reference=control period) 1.04 0.91 1.21 0.55 
     
Time (linear trend) 1.00 0.91 1.10 0.97 
     
Season (reference=spring)        
summer 0.88 0.79 0.98 0.02 
autumn 1.03 0.91 1.17 0.61 
winter 1.13 1.04 1.22 0.005 
     
Age-group (reference=80+)        
18-34 0.15 0.11 0.20 <0.0001 
35-49 0.30 0.25 0.36 <0.0001 
50-64 0.36 0.32 0.40 <0.0001 
65-79 0.56 0.52 0.60 <0.0001 
     
Sex (reference=male) 0.86 0.80 0.92 <0.0001 
     
Charlson comorbidity score (reference=0)        
1 1.82 1.58 2.09 <0.0001 
2 2.18 1.90 2.50 <0.0001 
3 2.80 2.43 3.22 <0.0001 
4 3.56 3.06 4.13 <0.0001 
5+ 5.76 5.03 6.59 <0.0001 
     
Hospital acquired AKI (reference 
community acquired) 0.94 0.88 1.0 0.06 
 
Table 3 
Results of multilevel logistic regression for mortality. The period in which the hospitals were exposed 
to the intervention as compared with the control (reference) period is shown in the first row. Effects 
are seen with season, age, gender and co-morbidity, but there is no time-effect on mortality over the 
study period. Cluster (hospital) was also included in the model.  
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Multilevel logistic regression for AKI progression   
  Odds ratio 95% CI P-value 
Intervention (reference=control period) 0.94 0.80 1.10 0.41 
     
Time (linear trend) 1.00 0.90 1.11 0.99 
     
Season (reference=spring)      
summer 0.99 0.89 1.10 0.86 
autumn 1.00 0.87 1.14 0.95 
winter 1.03 0.94 1.13 0.58 
     
Age-group (reference=80+)      
18-34 0.93 0.76 1.13 0.45 
35-49 1.27 1.08 1.48 0.003 
50-64 1.20 1.08 1.34 0.001 
65-79 1.19 1.09 1.30 <0.0001 
     
Sex (reference=Male) 0.83 0.77 0.90 <0.0001 
     
Charlson comorbidity score (reference=0)      
1 1.18 1.03 1.36 0.018 
2 1.58 1.38 1.81 <0.0001 
3 1.85 1.60 2.14 <0.0001 
4 2.30 1.98 2.68 <0.0001 
5+ 2.32 2.03 2.66 <0.0001 
     
Hospital acquired AKI (reference community 
acquired) 0.96 0.89 1.03 0.26 
 
Table 4 
Results of multilevel logistic regression for AKI progression. AKI progression was defined as AKI 
stage 1 or 2 that worsened to a higher stage of AKI. The period in which the hospitals were exposed 
to the intervention as compared with the control (reference) period is shown in the first row. Cluster 
(hospital) was also included in the model. 
 
